Kaisa Litonius
Articles
-
Oct 4, 2024 |
ascpt.onlinelibrary.wiley.com | Kati Kristiansson |Kaisa Litonius |Noora Kulla |Petra Falkenbach
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Majority of people carry at least one actionable pharmacogenetic genotype, and the value of pharmacogenetic testing is widely accepted. However, only few studies have assessed the utility and cost-effects of pre-emptive pharmacogenetic testing in a scenario where all patients admitted to hospital would be genotyped. WHAT QUESTION DID THIS STUDY ADDRESS?
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →